AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
ACIU(NASDAQ:ACIU) AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
September 4, 2025Finance
Read more →'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA
ACIUMay 16, 2025
Read more →HC Wainwright & Co. Maintains Buy on AC Immune, Lowers Price Target to $12
ACIUMay 1, 2025
Read more →AC Immune Q1 EPS $(0.21) Misses $(0.20) Estimate, Sales $1.10M Beat $300.67K Estimate
ACIUApril 30, 2025
Read more →HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
ACIUApril 3, 2025
Read more →AC Immune Reports Further Interim Results From Phase 2 Trial Of ACI-7104.056 Active Immunotherapy In Early Parkinson's Disease; Says Repeated Immunizations Amplify The Anti-a-syn Antibody Response
ACIUApril 2, 2025
Read more →HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
ACIUMarch 14, 2025
Read more →AC Immune FY24 EPS CHF(0.51) vs CHF(0.64) YoY; Contract Revenues CHF27.3M
ACIUMarch 13, 2025
Read more →HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
ACIUNovember 15, 2024
Read more →S&P 500 Moves Lower; US Crude Oil Inventories Increase
ACIUNovember 14, 2024
Read more →AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
ACIUAC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease.
November 14, 2024
Read more →AC Immune Reports Interim Results From Phase 2 Trial Of ACI-7104.056 Active Immunotherapy In Early Parkinson's Disease; Well Tolerated With No Clinically Relevant Safety Issues Reported, Says 100% Of Patients Responded Against The Target Antigen
ACIUNovember 14, 2024
Read more →HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
ACIUNovember 6, 2024
Read more →AC Immune Q3 EPS $0.06 Beats $(0.23) Estimate, Sales $29.44M Beat $1.74M Estimate
ACIUNovember 5, 2024
Read more →Recap: AC Immune Q1 Earnings
ACIUAC Immune (NASDAQ:ACIU) reported its Q1 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
April 28, 2022
Read more →AC Immune Reports Q1 EPS CHF(0.23), Same YoY
ACIUApril 28, 2022
Read more →